Wong CY - Search Results

1

Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.

Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ. Wong CY, et al. Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):815-20. doi: 10.1007/s00259-002-0787-4. Epub 2002 Mar 29. Eur J Nucl Med Mol Imaging. 2002. PMID: 12029557 Clinical Trial.

2

Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET.

Wong CY, Salem R, Qing F, Wong KT, Barker D, Gates V, Lewandowski R, Hill EA, Dworkin HJ, Nagle C. Wong CY, et al. Among authors: wong kt. J Nucl Med. 2004 Nov;45(11):1892-7. J Nucl Med. 2004. PMID: 15534060 Free article. Clinical Trial.

3

Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging.

Wong CY, Qing F, Savin M, Campbell J, Gates VL, Sherpa KM, Lewandowski RJ, Nagle C, Salem R. Wong CY, et al. J Vasc Interv Radiol. 2005 Aug;16(8):1101-6. doi: 10.1097/01.RVI.0000168104.32849.07. J Vasc Interv Radiol. 2005. PMID: 16105922

4

Regional yttrium-90 microsphere treatment of surgically unresectable and chemotherapy-refractory metastatic liver carcinoma.

Wong CY, Savin M, Sherpa KM, Qing F, Campbell J, Gates VL, Lewandowski RJ, Cheng V, Thie J, Fink-Bennett D, Nagle C, Salem R. Wong CY, et al. Cancer Biother Radiopharm. 2006 Aug;21(4):305-13. doi: 10.1089/cbr.2006.21.305. Cancer Biother Radiopharm. 2006. PMID: 16999596 Clinical Trial.

5

Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography predicts extrahepatic metastatic potential of colorectal metastasis: a practical guide for yttrium-90 microsphere liver-directed therapy.

Wong CY, Gates VL, Tang B, Campbell J, Qing F, Lewandowski RJ, Thie J, Ho CL, Savin M, Salem R. Wong CY, et al. Cancer Biother Radiopharm. 2010 Apr;25(2):233-6. doi: 10.1089/cbr.2009.0735. Cancer Biother Radiopharm. 2010. PMID: 20423237

6

Time sensitivity: a parameter reflecting tumor metabolic kinetics by variable dual-time F-18 FDG PET imaging.

Wong CY, Noujaim D, Fu HF, Huang WS, Cheng CY, Thie J, Dalal I, Chang CY, Nagle C. Wong CY, et al. Mol Imaging Biol. 2009 Jul-Aug;11(4):283-90. doi: 10.1007/s11307-009-0206-3. Epub 2009 Mar 27. Mol Imaging Biol. 2009. PMID: 19326175

7

Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).

Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong CY. Agarwal M, et al. Among authors: wong cy. Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):691-8. doi: 10.1007/s00259-009-1291-x. Epub 2009 Nov 14. Eur J Nucl Med Mol Imaging. 2010. PMID: 19915840 Free PMC article.

8

Neurocysticercosis on 18F-FDG PET/MRI: co-registered Images.

Jolepalem P, Wong CY. Jolepalem P, et al. Among authors: wong cy. Clin Nucl Med. 2014 Jan;39(1):e110-3. doi: 10.1097/RLU.0b013e3182817ad8. Clin Nucl Med. 2014. PMID: 23579982

9

Atypical Presentation of Sarcoidosis on ¹⁸F-FDG PET/CT.

Jolepalem P, McLean KZ, Wong CY. Jolepalem P, et al. Among authors: wong cy. J Nucl Med Technol. 2014 Jun;42(2):114-5. doi: 10.2967/jnmt.113.132654. Epub 2014 Mar 13. J Nucl Med Technol. 2014. PMID: 24627413 Free article. Review.

10

Combined CT-PET criteria for myocardial viability and scar: a preliminary report.

Wong CY, Tatini VR, Bis K. Wong CY, et al. Int J Cardiovasc Imaging. 2004 Dec;20(6):487-91. doi: 10.1007/s10554-004-2784-0. Int J Cardiovasc Imaging. 2004. PMID: 15856631

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

735 results

Search Page

Filters